CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases

Paratore, Sabrina; Banna, Giuseppe Luigi; D’Arrigo, Mabel; Saita, S; Iemmolo, Rosario; Lucenti, Letizia; Bellia, Domenico; Lipari, Helga; Buscarino, Calogero; Cunsolo, Rosario; Cavallaro, Sebastiano

doi:10.3233/cbm-2011-0232

Cited by 29 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, we have investigated the expression of CXCR4, together with those of its ligand CXCL12, in primary NSCLC specimens of patients with and without brain metastasis, using a quantitative double-labeling immunofluorescence analysis [70]. We matched a M0 NSCLC group with a M1 NSCLC group, using clinical and pathological characteristics (gender, age, histology, T stage, and N stage) as consistent as possible.…”

Section: Cxcr4 and Cxcr12 In Nsclc Metastasis To The Brainmentioning

confidence: 99%

“…In order to assess this hypothesis, we performed Receiver Operating Characteristics (ROC) analysis in order to define optimal cut-off values for CXCL12 and CXCR4 immunoreactivities that could discriminate between NSCLC patients without and with brain metastasis [70]. ROC curves showed a good diagnostic accuracy and adequate predictive power for both CXCL12 and CXCR4, supporting their potential use as prognostic markers.…”

Section: Cxcr4 and Cxcr12 In Nsclc Metastasis To The Brainmentioning

confidence: 99%

See 1 more Smart Citation

CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain

Cavallaro

2013

IJMS

Self Cite

View full text Add to dashboard Cite

Lung cancer represents the leading cause of cancer-related mortality throughout the world. Patients die of local progression, disseminated disease, or both. At least one third of the people with lung cancer develop brain metastases at some point during their disease, even often before the diagnosis of lung cancer is made. The high rate of brain metastasis makes lung cancer the most common type of tumor to spread to the brain. It is critical to understand the biologic basis of brain metastases to develop novel diagnostic and therapeutic approaches. This review will focus on the emerging data supporting the involvement of the chemokine CXCL12 and its receptor CXCR4 in the brain metastatic evolution of non-small-cell lung cancer (NSCLC) and the pharmacological tools that may be used to interfere with this signaling axis.

show abstract

Section: Cxcr4 and Cxcr12 In Nsclc Metastasis To The Brainmentioning

confidence: 99%

Section: Cxcr4 and Cxcr12 In Nsclc Metastasis To The Brainmentioning

confidence: 99%

CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain

Cavallaro

2013

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since chemokine receptors have already been shown to play a role in metastasis, there is little doubt about their role in brain metastasis as well. The chemokine receptor CXCR4 is overexpressed in brain metastatic sections of patients with non-small cell lung cancer [176, 177]. Also, CXCR4 is overexpressed in brain metastatic sections of patients with colorectal cancer [165].…”

Section: Introductionmentioning

confidence: 99%

Chemokines in tumor progression and metastasis

et al. 2013

View full text Add to dashboard Cite

Chemokines play a vital role in tumor progression and metastasis. Chemokines are involved in the growth of many cancers including breast cancer, ovarian cancer, pancreatic cancer, melanoma, lung cancer, gastric cancer, acute lymphoblastic leukemia, colon cancer, non-small lung cancer and non-hodgkin's lymphoma among many others. The expression of chemokines and their receptors is altered in many malignancies and leads to aberrant chemokine receptor signaling. This review focuses on the role of chemokines in key processes that facilitate tumor progression including proliferation, senescence, angiogenesis, epithelial mesenchymal transition, immune evasion and metastasis.

show abstract

“…CXCL12 has also an influence on the migratory behaviour of human lung cancer cells and primary lung epithelial cells from rats in vitro by inducing the production of matrix metalloproteinases (MMPs) (Huang et al., ; Ghosh et al., ). Decreased tumour growth and the suppression of metastases mediated by numerous anti‐tumourous drugs specifically blocking chemokine receptors or their ligands supported the role of these molecules in the metastatic spread to the brain where they might serve as promising targets (Balkwill, ; Kakinuma and Hwang, ; Zlotnik, ; Chen et al., ; Paratore et al., ). However, these therapeutic compounds have not been included into clinical trials so far.…”

Section: The Multistep Process Of Bm Formationmentioning

confidence: 99%

Control of the blood–brain barrier function in cancer cell metastasis

Blecharz

Colla

Rohde

et al. 2015

Biology of the Cell

View full text Add to dashboard Cite

Cerebral metastases are the most common brain neoplasms seen clinically in the adults and comprise more than half of all brain tumours. Actual treatment options for brain metastases that include surgical resection, radiotherapy and chemotherapy are rarely curative, although palliative treatment improves survival and life quality of patients carrying brain-metastatic tumours. Chemotherapy in particular has also shown limited or no activity in brain metastasis of most tumour types. Many chemotherapeutic agents used systemically do not cross the blood-brain barrier (BBB), whereas others may transiently weaken the BBB and allow extravasation of tumour cells from the circulation into the brain parenchyma. Increasing evidence points out that the interaction between the BBB and tumour cells plays a key role for implantation and growth of brain metastases in the central nervous system. The BBB, as the tightest endothelial barrier, prevents both early detection and treatment by creating a privileged microenvironment. Therefore, as observed in several in vivo studies, precise targetting the BBB by a specific transient opening of the structure making it permeable for therapeutic compounds, might potentially help to overcome this difficult clinical problem. Moreover, a better understanding of the molecular features of the BBB, its interrelation with metastatic tumour cells and the elucidation of cellular mechanisms responsible for establishing cerebral metastasis must be clearly outlined in order to promote treatment modalities that particularly involve chemotherapy. This in turn would substantially expand the survival and quality of life of patients with brain metastasis, and potentially increase the remission rate. Therefore, the focus of this review is to summarise the current knowledge on the role and function of the BBB in cancer metastasis.

show abstract

CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases

Cited by 29 publications

References 43 publications

CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain

CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain

Chemokines in tumor progression and metastasis

Control of the blood–brain barrier function in cancer cell metastasis

Contact Info

Product

Resources

About